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Abstract - Cross-over animal trials were performed with intravenous and oral administration of deoxynivalenol-
3-β-D-glucoside (DON3G) and deoxynivalenol (DON) to broiler chickens and pigs. Systemic plasma 
concentrations of DON, DON3G and de-epoxy-DON were quantified using liquid chromatography-tandem mass 
spectrometry. Liquid chromatography coupled to high-resolution mass spectrometry was used to unravel 
phase II metabolism of DON. Additionally for pigs, portal plasma was analysed to study presystemic hydrolysis 
and metabolism. Data were processed via tailor-made compartmental toxicokinetic models. The results in 
broiler chickens indicate that DON3G is not hydrolysed to DON in vivo. Furthermore, the absolute oral 
bioavailability of DON3G in broiler chickens was low (3.79±2.68%) and comparable to that of DON 
(5.56±2.05%). After PO DON3G administration to pigs, only DON was detected in plasma, indicating a complete 
presystemic hydrolysis of the absorbed fraction of DON3G. However, the absorbed fraction of DON3G, 
recovered as DON, was approximately 5 times lower than after PO DON administration, 16.1±5.4% compared 
to 81.3±17.4%. Analysis of phase II metabolites revealed that biotransformation of DON and DON3G in pigs 
mainly consists of glucuronidation, whereas in chickens predominantly conjugation with sulfate occurred. The 
extent of phase II metabolism is notably higher for chickens than for pigs, which might explain the differences 
in sensitivity of these species to DON. Although in vitro studies demonstrate a decreased toxicity of DON3G 
compared to DON, the species dependent toxicokinetic data and in vivo hydrolysis to DON illustrate the 
toxicological relevance and consequently the need for further research to establish a tolerable daily intake. 
 






Mycotoxin contamination of food and feed has been classified by several authors as the most important 
chronic dietary risk for human and animal health. The Fusarium mycotoxin deoxynivalenol (DON) is one of the 
most frequently occurring mycotoxins, contaminating 56% of feed and feed raw materials worldwide 
(Schatzmayr and Streit 2013). Additionally, feed can be contaminated with modified forms of DON, such as 
deoxynivalenol-3-β-D-glucoside (DON3G), causing a possible underestimation of the degree of contamination. 
Following a request from the European Commission, the risks to human and animal health related to modified 
forms of the Fusarium mycotoxins zearalenone, nivalenol, T-2 and HT-2 toxin and fumonisins were evaluated 
by the European Food Safety Authority Panel on Contaminants in the Food Chain (EFSA CONTAM Panel). The 
panel considered it appropriate to assess human exposure to modified forms of the various toxins in addition 
to the parent compounds, because modified forms may be hydrolysed into the parent compounds or released 
from the matrix during digestion. However, no risk assessment for modified forms of DON is currently available 
(EFSA CONTAM Panel 2014). Concerning acetylated forms of DON, 3-acetyl-deoxynivalenol (3ADON) and 15-
acetyl-deoxynivalenol (15ADON), both ADONs were completely absorbed and presystemically hydrolysed to 
DON in pigs (Broekaert et al. 2015b). In chickens, for both ADONs a higher absorbed fraction was observed 
compared to DON, as well as a presystemic hydrolysis of 3ADON and 15ADON to DON of 100% and 75.4%, 
respectively (Broekaert et al. 2015b). 
Recent occurrence data (2010-2014) for DON and DON3G have been reviewed for unprocessed cereals, such as 
wheat, maize, barley, oat, rye and spelt (Broekaert et al. 2015a). Observed incidence, average concentration 
and maximum detected concentration for DON and DON3G were 84%, 458 µg/kg, 27,088 µg/kg and 55%, 85 
µg/kg, 170 µg/kg, respectively. DON3G concentrations exceeding those of free DON have been detected in 
some hard red spring wheat samples (Sasanya et al. 2008), which indicate its high prevalence.  
The susceptibility of animal species to DON can be ranked in the following decreasing order: pigs > mice > rats > 
poultry ≈ ruminants (Pinton and Oswald 2014). The toxicity of DON depends on its ability to efficiently cross 
biological barriers in humans and animals, such as the intestinal and the blood-brain barrier. At the cellular 
level, DON primarily inhibits protein synthesis. Consequently, fast dividing cells such as intestinal epithelial and 
immune cells will be more susceptible to the detrimental effects of DON (Maresca 2013; Pestka 2010; Rotter et 
al. 1996). The cellular toxicity is mainly attributed to the presence of the epoxide moiety (Pestka 2010; Ueno et 
al. 1973). This functional group allows DON, and trichothecenes in general, to bind to ribosomes, and inhibit 
peptide bond formation. Additionally, DON in lower doses causes a ‘ribotoxic stress response’, leading to 
proinflammatory responses (Pestka 2008). Presumably glucosylation of DON greatly reduces its toxicity. The 
phytotoxicity of DON and DON3G was studied by means of a wheat germ extract-coupled in vitro 
transcription/translation system. While 1 µM of DON significantly decreased translation by 63%, 5 µM and 20 
µM of DON3G resulted in a translation decrease of only 3.1% and 8.0%, respectively (Poppenberger et al. 
2003). In a growth test with algal cells, 80 µM of DON3G, unlike an equimolar amount of DON, did not 
significantly alter growth (Suzuki and Iwahashi 2015). Decreased toxicity has also been observed in mice, where 
DON3G was largely incapable of evoking cytokine or chemokine responses in the spleen of mice orally gavaged 
with 2.5 mg/kg body weight (bw), in contrast to DON, except for slight elevations in IL-1β mRNA expression 
(Wu et al. 2014). Recently, in silico analysis suggested that DON3G, unlike DON, was unable to bind to the 
ribosome peptidyl transferase centre (Pierron et al. 2015). Additionally, comparative cytotoxicity of DON and 
DON3G was assessed on both proliferative Caco-2 cells by means of quantitation of the ATP present. After 48 h 
exposure to DON, an IC50 of 1.3 µM (0.384 µg/mL) was observed in proliferative Caco-2 cells. In contrast, no 
cytotoxicity was observed with up to 10 µM of DON3G (Pierron et al. 2015). 
Regarding the hydrolysis of DON3G to DON, different in vitro studies reported that DON3G was not hydrolysed 
to DON in the human upper gastrointestinal (GI) tract by means of acid, stomach and gut juice, or recombinant 
human cytosolic β-glucosidase (Berthiller et al. 2011; Dall'Erta et al. 2013; De Angelis et al. 2014; De Nijs et al. 
2012). Regarding the human lower GI tract, some in vitro experiments indicate that hydrolysis can take place 
and that the intestinal microbiota composition and their abundance can play an important role (Abbott 2004; 
Berthiller et al. 2011; Dall'Erta et al. 2013; Gratz et al. 2013; Hattori and Taylor 2009). In vitro models do not 
take into account important physiological and anatomical factors within and between different animal species 
and humans, such as intestinal mucosa and luminal content composition (enzymes, microbiota), blood flow in 
internal organs and enterohepatic recirculation (Gonzalez-Arias et al. 2013). To estimate these factors and 
especially the interactions between them, species-specific in vivo trials remain mandatory. Versilovskis et al. 
(2012) reported a first DON3G in vivo study in which two rats were fed 25 µg of DON3G by oral gavage, 
followed by blood collection at 17 and 55 min post-administration. DON was detected in the stomach albeit at 
only 2% of the applied dose. This confirms the conclusions of the in vitro studies, i.e. hydrolysis of DON3G in 
the stomach is negligible. Further down in the GI tract, DON3G could only be detected at 2-3% of the applied 
dose in the small intestine and at 1-2% in the colon. This remarkable decrease of DON3G in the small intestine 
is probably due to the presence of intestinal β-glucosidases (Versilovskis et al. 2012). Nagl et al. (2012) orally 
administered DON and an equimolar dose of DON3G to six rats, followed by urine and faeces collection over a 
period of two days. After PO administration of DON3G, less than 4% of the administered dose was recovered in 
urine, of which 35% as DON, 33% as DON-glucuronide (DON-GlcA), 24% as de-epoxy-deoxynivalenol (DOM-1) 
and 8% as DON3G. The presence of urinary DON clearly demonstrates the hydrolysis upon ingestion. In 
comparison, after PO DON administration, 15% of the dose was recovered in urine as DON-GlcA, DON and 
DOM-1, indicating a relatively low oral bioavailability for DON3G compared to DON in rats. Analysis of faecal 
samples of rats dosed with DON3G revealed that the vast majority of the metabolites of DON3G were excreted 
as DON and DOM-1 (sum: 99.5 ± 0.4%). Only traces of DON3G were detected, indicating that intestinal 
microbiota are effective in hydrolysing this masked mycotoxin in rats (Nagl et al. 2012). Recently, the results in 
rat were supported by in vivo experiments performed in pig by the same research group (Nagl et al. 2014). 
After intravenous (IV) administration of DON3G, no DON was detected in plasma, indicating that systemic 
hydrolysis of DON3G is negligible. After oral administration of DON3G, 40.3% of the dose was recovered in 
urine of which 2.6% as DON3G, next to DON (21.6%), DON-15-glucuronide (DON15GlcA) (6.8%), DOM-1 (5.9%) 
and DON-3-glucuronide (DON3GlcA) (3.4%) (Nagl et al. 2014). Consequently, it was concluded that in vivo 
cleavage of DON3G predominantly occurs in the (lower) digestive tract. Oral bioavailability was lower for 
DON3G than for DON, deduced from the recovered DON equivalent amounts in urine, namely 84.8% for DON 
and 40.3% for DON3G (Nagl et al. 2014). Moreover, the oral bioavailability for both compounds in pig was 
remarkably higher than in rat.  
However, both study designs in rat and pig do not allow determination of the site of hydrolysis (GI microbiota, 
GI tissues, portal blood, liver, systemic blood). Sampling portal blood would offer a huge advantage as it would 
allow to differentiate between presystemic and systemic hydrolysis and therefore significantly contribute to 
the understanding of the (pre)systemic hydrolysis of DON3G. Transsplenic portal vein catheterisation in pigs 
has previously been described (Gasthuys et al. 2009) and was used to study the presystemic metabolisation of 
xenobiotics (Reyns et al. 2009). Therefore, portal vein catheterisation offers a valuable tool to study possible 
presystemic hydrolysis of DON3G in pigs. 
Currently, literature reports regarding the toxicokinetics of DON3G in humans and other animal species, such 
as broiler chickens, are scarce. Warth et al. performed a study with a human volunteer consuming a diet 
naturally contaminated with 138 µg DON/day, 7 μg DON3G/day and 20 µg 3ADON/day. DON3G, in contrast to 
DON, could not be detected in urine (Warth et al. 2013). For broiler chickens no data is available, although 
poultry have a high exposure to DON3G given their mainly cereal based diet. The GI anatomy, physiology and 
distinct microbiota species composition and abundance of poultry further contribute to the relevance of 
performing research in these species. 
The goal of this study was to determine the absolute oral bioavailability, the degree of hydrolysis and the main 
toxicokinetic parameters of DON3G in broiler chickens and pigs. Additionally portal vein catheterisation in pigs 
allowed determination of the site of presystemic hydrolysis.  
Materials and methods 
Standards, reagents and solutions 
DON (>99% purity) was obtained from Fermentek (Jerusalem, Israel). DON3G was enzymatically 
synthesized, purified and verified using nuclear magnetic resonance (NMR) and liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) (Michlmayr et al. 2015). No remaining DON (<0.05%) was detected in the 
produced DON3G. DON and DON3G were dissolved in analytical-grade ethanol (EtOH) (Merck, Brussels, 
Belgium), yielding a stock solution of 10 mg/mL and were used for animal trials and analytical experiments. 
DOM-1 (50 µg/mL) and 13C15-DON (stable isotopically labelled internal standard, IS, 50 µg/mL) stock solutions in 
acetonitrile were purchased from Sigma-Aldrich (Diegem, Belgium). All stock solutions were stored at ≤-15 °C. 
Individual working standard solutions of 10 µg/mL, used for the analytical experiments, were prepared by 
diluting the above stock solutions with UHPLC-MS grade acetonitrile (Biosolve, Valkenswaard, The 
Netherlands). All working standard solutions were stored at ≤-15 °C. Standard mixture working solutions 
containing DON, DON3G and DOM-1 of 1 and 0.1 µg/mL were prepared by mixing appropriate dilutions of the 
individual working standard solutions in UHPLC-MS acetonitrile, stored at 2-8 °C. Solutions of DON in 
acetonitrile have been reported to be stable for 24 months at room temperature (Widestrand and Pettersson 
2001). Water, methanol and glacial acetic acid were of UHPLC-MS grade (Biosolve). Microfilters (GV-PVDF 0.22 
µm) were obtained from Millipore (Overijse, Belgium). 
Animal trials 
Broiler chickens 
Six broiler chickens (Ross 308) were purchased from the Institute for Agriculture and Fisheries Research (Melle, 
Belgium) at the age of 3 weeks, as hatched. Water and feed were given ad libitum. The pen was climate 
controlled with temperatures between 21 and 25 °C, a relative humidity between 40 and 60% and an applied 
light schedule similar to commercial installations (18 h light/6 h dark). After a one week acclimatisation period, 
the animals had an average bw ± standard deviation (SD) of 1400 ± 131 g, and three broiler chickens were 
treated with DON3G by IV bolus injection in the vena basilica, and three broiler chickens received DON3G PO 
by means of gavage in the crop. After a wash-out period of 1 day, a cross-over design was applied, which 
resulted in a PO and IV administration of DON3G in each of the six broiler chickens. Next, a second wash-out 
period of three days was respected, and the same broiler chickens were subjected to an identical two-way 
cross-over (IV and PO) study with DON. The administered doses were based on the EU maximum guidance level 
of 5 mg DON/kg poultry feed (European Commission 2006). Given an average feed consumption of 4-week-old 
broiler chickens of 100 g feed/kg bw/day, 500 µg DON/kg bw was administered. For DON3G, an equimolar dose 
of 774 µg/kg bw was administered. The calculated volume of stock solution (10 mg/mL in EtOH) was diluted 
with saline (0.9% NaCl) (VWR, Leuven, Belgium) up to a volume of 0.5 mL (IV) or 1 mL (PO). Feed was deprived 
12 h before administration and until 3 h post administration (p.a.). After oral administration of the toxins, 1 mL 
of tap water was administered to flush the gavage syringe and tube. Blood (0.5-1 mL) was sampled from the leg 
vein (vena metatarsalis plantaris superficialis) by venipuncture at 0 min (before administration) and at 5, 10, 
20, 30, 45, 60, 90, 120 and 180 min p.a. Blood samples were centrifuged (2851 x g, 10 min, 4 °C) and plasma 
was stored at ≤ -15 °C until analysis. 
Pigs 
For the pig study, six clinically healthy male pigs (11 weeks of age, 26.3 ± 1.8 kg bw) were individually 
housed and were provided feed and water ad libitum. Natural lighting was applied, the enclosure was climate 
controlled to keep the temperature between 20 and 24 °C and the relative humidity between 20 and 40%. 
After a one week acclimatisation period, double lumen catheters were surgically placed into the vena jugularis 
of all six pigs. Additionally, in four of the six pigs a single lumen catheter was placed into the vena porta to 
study presystemic hydrolysis and biotransformation. The surgical procedure was as previously described 
(Gasthuys et al. 2009). After a period of two days, the animals were treated with DON3G by IV bolus injection 
using one lumen of the double lumen jugular catheters, or PO by means of gavage in the stomach, in a two way 
cross-over design. After DON3G administration, an identical cross-over administration with DON was set up in 
the same animals and respecting a wash-out period of 24 h between treatments. Twelve h before 
administration of the mycotoxins, the animals were fasted until 4 h p.a. The administered doses were 
calculated as for the broiler chicken trial. The EU maximum guidance level in pig feed is 0.9 mg/kg DON 
(European Commission 2006). Pigs at 12 weeks of age consume on average 40 g feed/kg bw/day. This resulted 
in the administration of 36 µg DON/kg bw. For DON3G, an equimolar dose of 55.7 µg/kg bw was administered. 
The calculated amount of toxin for each animal, dissolved in EtOH at 10 mg/mL, was diluted with saline to a 
volume of 1 mL (IV) or 10 mL (PO). After oral administration of the toxins, 50 mL of tap water was administered 
to flush the gavage syringe and tube. Blood (1-2 mL) was sampled via the other lumen of the jugular catheter 
and the vena porta catheter at 0 min (before administration) and at 5, 10, 20, 30, 45, 60, 90, 120, 240, 360 and 
480 min p.a. Blood samples were centrifuged (2851 x g, 10 min, 4 °C) and plasma was stored at ≤ -15 °C until 
analysis. 
The chicken and pig animal trials were approved by the Ethics Committee of the Faculty of Veterinary 
Medicine and Bioscience Engineering of Ghent University (EC2013/64 and EC2015/14, respectively).  
Plasma sample preparation 
 Blank plasma was obtained by the collection of heparin treated blood from six different broiler 
chickens and pigs. The animals were fasted 12 h prior to blood collection. Plasma was obtained by 
centrifugation (2851 x g, 10 min, 4 °C) of the blood. The blank plasma was pooled, homogenised and stored at ≤ 
-15 °C until use for the preparation of matrix-matched calibrators and quality control samples.  
Calibrator and quality control samples. To 250 µL of blank plasma, 25 µL of a 100 ng/mL IS working 
solution (13C15-DON) and appropriate volumes of the standard mixture working solutions (1, 10 100 and 1000 
ng/mL) were added to obtain calibrator samples with mycotoxin concentrations of 0.1, 0.5, 1, 5, 10, 50, 100 
and 500 ng/mL. After vortex mixing, acetonitrile was added up to a volume of 1 mL to precipitate plasma 
proteins. The samples were vortex mixed again, followed by a centrifugation step (10 min at 8517 x g, 4 °C). 
The supernatant was transferred to a new tube and evaporated to dryness under nitrogen at 45 °C. The dry 
residue was then redissolved in 200 µL of UHPLC-MS grade water, micro-filtrated and 10 µL was injected onto 
the LC-MS/MS instrument. 
Incurred samples. To 250 µL of plasma, 25 µL of a 100 ng/mL IS working solution were added. 
After vortex mixing, the samples were subjected to the same sample preparation procedure as the calibrator 
samples. 
Blank samples. After the addition of 750 µL of acetonitrile to 250 µL of blank plasma, the samples 
were extracted in the same way as the calibrator samples. 
LC-MS/MS analysis and validation 
 Separation of DON, 13C15-DON, DON3G and DOM-1 was achieved on a Hypersil Gold (reversed-phase) 
(50 x 2.1 mm i.d., 1.9 μm) column with a guard column (10 x 2.1 mm i.d., 5 μm) of the same type. Chicken and 
pig plasma were analysed on an Acquity UPLC® system coupled to a Xevo® TQ-S MS instrument (Waters, Zellik, 
Belgium).  
All compounds were eluted with a gradient of water containing 0.3% glacial acetic acid (mobile phase A) 
and methanol containing 0.3% glacial acetic acid (mobile phase B), at a flow rate of 300 µL/min. The following 
gradient elution program was run: 0-1 min, 5% B; 1.0-1.1 min, linear gradient to 12% B; 1.1-5.0 min, 12% B; 5.0-
5.1 min, linear gradient to 50% B; 5.1-8.0 min, 50% B; 8.0-8.1 min, linear gradient to 95% B; 8.1-10.0 min, 95% 
B; 10.0-10.1 min, linear gradient to 5% B; 10.1-12.0 min, 5% B. The MS was operated in the multiple reaction 
monitoring (MRM) mode with two ion transitions for each target analyte as presented in Table 1. Instrumental 
and compound specific parameters were optimized by the direct infusion of 10 ng/mL standard solutions in 
methanol/ water (50/50, v/v) + 0.3% glacial acetic acid with a flow rate of 10 µL/min. For the Xevo TQ-S, the 
desolvation gas flow rate was fixed to 800 L/h with a temperature of 550 °C, the cone gas flow rate was set at 
150 L/h, capillary voltage was optimised at 3.0 kV and a collision gas flow of 0.15 mL/min was used. Dwell times 
of 44 - 52 ms/transition were chosen. Compound specific MS parameters, together with precursor and product 
ions used for quantification and qualification, are given in Table 1. DON, 13C15-DON and DOM-1 were detected 
in positive electrospray ionisation mode (ESI+) as the protonated precursor ion [M+H]+, DON3G was measured 
in ESI- as [M+CH3COO]- adduct.  
Given the unavailability of reference materials, validation was performed on fortified blank pig and 
broiler plasma samples. Both recommendations as defined by the European Community (Commission Decision 
2002; Heitzman 1994) and the Veterinary International Conference on Harmonisation (VICH 2009) served as 
validation guidelines. The developed method was single laboratory validated.  
Linearity of the response of the compounds was assessed by means of three matrix-matched 
calibration curves consisting of eight calibration points in the range of 0.1-500 ng/mL. The correlation 
coefficients (r) and goodness-of-fit coefficients (gof) were determined, limits were set at ≥0.99 and ≤20%, 
respectively.  
Within-day accuracy & precision were determined by analyzing six samples fortified at a low 
concentration level (limit of quantitation (LOQ) of the compounds) and at a high concentration level (100 
ng/mL). Values for the relative standard deviation (RSD) could not exceed 2/3 of the RSDmax, calculated 
according to the Horwitz equation, i.e. RSDmax = 2(1−0.5logConc) × 2/3. The acceptance criteria for accuracy were: 
−30% to +10% and −20% to +10% for concentrations between 1 and 10 ng/mL, and ≥10 ng/mL, respectively. 
Between-day accuracy & precision were assessed by analyzing the low and high concentration levels in 
threefold on three consecutive days (n=3x3). The acceptance criteria for accuracy were identical to the values 
given above and RSD values could not exceed RSDmax= 2(1−0.5logConc). 
The LOQ was calculated as the lowest concentration for which the method had acceptable results with 
regards to accuracy and precision. It was determined by spiking six blank plasma samples. The LOQ was also 
established as the lowest point of the calibration curve. The limit of detection (LOD) was calculated using the 
samples spiked at the LOQ level (n=6) corresponding to the concentration that could be determined with a 
signal-to-noise (S/N) ratio of 3.  
Carry-over was evaluated by analysing a mixture of mobile phase A and B (50/50; v/v) directly after the 
highest calibrator (500 ng/mL).  
The specificity, the capability of the method to distinguish signals of the analytes from any other 
substances or interferences, was determined on six blank plasma samples. For an acceptable specificity the S/N 
ratio of possible interfering peaks with similar retention times in these samples could not exceed the S/N ratio 
of 3. 
Recovery and matrix effects. Two types of matrix-matched calibration curves were prepared by spiking 
blank calibrator samples before and after extraction. A third calibration curve was prepared in standard 
solution. All curves consisted of eight calibration points in the range of 0.1-500 ng/mL. The slopes of these 
calibration curves (external calibration, without IS) were compared to calculate the apparent recovery 
(RA = 100 × slope spiked before extraction/slope standard solution), the matrix effect denoted as signal 
suppression/enhancement (SSE = 100 × slope spiked after extraction/slope standard solution) and the recovery 
of the extraction step (RE = 100 × slope spiked before extraction/slope spiked after extraction). Regarding SSE, 
values ≤ 1 indicate ion suppression due to matrix effect, values ≥ 1 indicate ion enhancement (Matuszewski et 
al. 2003). 
High resolution mass spectrometry 
To determine the presence of phase II metabolites, i.e. glucuronide and sulfate conjugates, high resolution 
mass spectrometry (HRMS) analysis was performed on pig and broiler chicken plasma samples from three 
animals after IV and PO administration for identification and semi-quantification of DON3G, DON and its 
metabolites. The methodology was similar as in a previously described study (Devreese et al. 2015). Sample 
treatment, HPLC column and mobile phases were identical to the LC-MS/MS analysis. However, a different 
gradient elution program was applied: 0-1.0 5% B, 1.0-4.0 linear to 80% B, 4.0-6.7 min 80% B, 6.7-7.0 linear 
gradient to 5% B, 7.0-10.0 5% B. The (U)HPLC consisted of an Accela type 1250 High Speed LC and autosampler 
coupled to an Exactive Orbitrap HR mass spectrometer, equipped with a heated electrospray ionisation (HESI) 
probe operating in the negative ionisation mode (all from Thermo Fischer Scientific, Breda, The Netherlands). 
Accurate masses for DON ([M+CH3COO]-), DOM-1 ([M+CH3COO]-), DON-3-sulfate and DON3GlcA, 355.1414, 
339.2016, 375.0755 and 471.1508, respectively, were based on Wan et al. and Devreese et al. (Devreese et al. 
2015; Wan et al. 2014). Accurate mass of DON3G ([M+CH3COO]-) was determined to be 517.19250 by direct 
infusion of a 10 µg/mL solution in mobile phase A and B (50/50, v/v). 
Toxicokinetic modeling and statistical analysis 
Toxicokinetic analysis on the LC-MS/MS data was performed using WinNonlin Professional version 5.2.1. 
(Pharsight, St-Louis, MO). Plasma concentrations below the LOQ were not taken into account. For the 
toxicokinetic analysis, all values were recalculated to their molar concentrations, expressed as nmol/mL. For 
the analysis of DON IV and PO data in chickens and pigs, and for DON3G IV and PO in chickens, a tailor-made 
two-compartmental model (central compartment (Vc) and peripheral compartment (Vp)) with first order 
absorption and first order elimination kinetics was applied. For the IV and PO administration of DON3G in pigs, 
a tailor-made one-compartmental model was fitted. Due to a lag time after PO DON3G administration to pigs, 
only terminal concentration points were above the LOQ. Consequently, it was not possible to calculate 
toxicokinetic parameters for the individual animals, and these parameters have been calculated simultaneously 
on all pooled pig PO DON3G data. As a result, no standard deviations could be calculated, instead coefficients 
of variation of the models’ predicted versus observed concentrations are provided. 
In Figure 1 and 2 a graphical representation of the constructed model is given for DON (IV & PO) and 
DON3G (IV & PO) in broiler chickens and pigs, respectively. 
A 1/ŷ weighing was applied for all calculations with both the chicken and pig data. For all the described 
models, the Gauss-Newton (Levenberg and Hartley) algorithm was used with a maximum of 50 iterations.  
The following primary and secondary toxicokinetic parameters were calculated for DON and DON3G after 
IV and PO administration: absorption rate constant (ka), intercompartmental flow (Q), total body clearance 
(CL), central volume of distribution (Vc), peripheral volume of distribution (Vp). FRAC is the absorbed fraction 
of the dose in either form (DON or DON3G). F indicates the absolute oral bioavailability, i.e. the fraction of DON 
or DON3G absorbed in the systemic circulation in its unchanged form. When both a central and peripheral 
volume of distribution were observed, the disposition rate constant (β) was calculated by dividing the Cl by the 
sum of Vc and Vp for each animal. When only a central volume of distribution was used, the elimination rate 
constant (ke) was calculated by dividing the Cl by the Vc for each animal. Presystemic hydrolysis (Pres. Hydr.) 
was the percentage of the total dose of DON3G that is hydrolysed presystemically to DON and absorbed as 
DON (%). Additionally, for PO data the descriptive toxicokinetic parameters maximal plasma concentration 
(Cmax) and time to Cmax (tmax) were given for DON. Elimination half lives (t1/2el) were calculated as 0.693/β or 
0.693/ke. 
Statistical analysis of FRAC, F, Cmax and tmax after DON3G administration compared to DON administration 
consisted of one-way ANOVA with post-hoc Scheffé tests (p value < 0.05) for both animal species (SPSS 20.0, 
IBM, Chicago, IL). Equality of variances criterion was determined by the Levene’s test for homogeneity of 
variances (p value > 0.01). 
Results and discussion 
LC-MS/MS method validation 
For the calibration model a linear, 1/x weighed, fitting was applied. The results for linearity (r and gof) and 
sensitivity (LOD and LOQ) are given in Table 2. The results for linearity were all in accordance with the 
acceptance criteria, with r ≥ 0.99 and gof ≤ 20%. For chicken plasma, the LOD varied from 0.11 (DOM-1) to 0.47 
(DON) ng/mL, whereas the LOQ was 1 ng/mL for all compounds. For pig plasma, LOD values ranged from 0.01 
(DON) to 0.28 (DOM-1) ng/mL, LOQ values were 0.1 (DON3G), 0.5 (DON) and 1 (DOM-1) ng/mL. 
The results for matrix effects (SSE), apparent recovery (RA) and extraction recovery (RE) are also depicted in 
Table 2. SSE values for all mycotoxins varied from 44 to 112%, which demonstrated the need for matrix-
matched calibration curves for a correct quantification. The matrix effects could be diminished by further 
optimizing the sample cleanup. However, a more elaborate cleanup tends to diminish the RE, possibly limiting 
the sensitivity of the method. Values for RE varied between 68.2 and 97.0% and RA values ranged from 41.8 to 
76.2%, with the majority of the latter deviation caused by SSE. 
Table 3 displays the results for accuracy (%) and precision (RSD, %). All results for chicken as well as pig plasma 
were within the acceptable ranges. The specificity test demonstrated that no interfering peaks were detected 
in the chromatographic elution zone of the analytes with S/N values ≥ 3 (results not shown).  
Carry-over was evaluated and for none of the compounds signals were detected that could interfere with the 
response/area of the analytes at their given retention time (results not shown). 
Toxicokinetic analysis 
The goal of this study was to determine the absolute oral bioavailability of DON3G and DON, the degree of in 
vivo hydrolysis of DON3G to DON (differentiating between presystemic GI, presystemic portal, presystemic 
hepatic and systemic hydrolysis) and the toxicokinetic parameters of both toxins in broiler chickens and pigs. A 
tailor-made compartmental toxicokinetic model was developed which offers the advantage, compared to non-
compartmental analysis, that for a given compound, PO and IV data can be fitted simultaneously for each 
animal allowing more reliable estimates as more data is available (Broekaert et al. 2015b). 
For broiler chickens, no adverse effects were observed during the animal trial following PO and IV bolus 
administration of the mycotoxins. Similarly, no adverse effects were observed during the pig trial following IV 
and PO DON3G administration and PO DON administration. Following IV dosing of DON, two out of six pigs 
vomited within 0.5 h p.a. However, this had no observable influence on the results as these pigs were IV dosed.  
Plasma concentration-time profiles for DON3G and DON in broiler chickens and pigs are presented in Figure 3. 
Each profile represents the mean of six animals ± SD for systemic plasma concentrations. Additionally for pigs, 
vena porta plasma concentration-time profiles are presented as mean of four animals ± SD. A first observation 
is the absence of DOM-1 in all analysed samples. The derived toxicokinetic results are shown in Table 4.  
The FRAC of PO administered DON and DON3G to chickens and PO administered DON to pigs was calculated 
using the tailor made model. However, the FRAC of DON3G to pigs could not be calculated by this model as 
after PO administration of DON3G only DON was recovered and after IV administration only DON3G. The FRAC 
was therefore calculated manually by correcting the area under the curve (AUC) of DON3G after IV 
administration by multiplying this value with its Cl, and by correcting the AUC of DON after PO DON3G dosing 
again by multiplying this value with its Cl and by correcting this ratio for the difference in molar masses, as 
shown in the formula below: 
 
 
The mean (±SD) absorbed fractions of DON and DON3G in broiler chickens were 5.56±2.05% and 3.79±2.68%, 
respectively. Moreover, for DON and DON3G in chickens, F was equal to FRAC as DON and DON3G are 
absorbed in their unchanged form. The FRAC of DON in pigs, 81.3±17.4% was also identical to the F. The FRAC 
of DON3G in pigs was 16.1±5.4%. However, as after PO DON3G administration only DON was recovered, F 
equals 0, indicating complete hydrolysis of the absorbed fraction. The higher observed FRAC values for pigs 
compared to chickens is an important contributing factor to the decreased sensitivity of the latter species, and 
may be partially caused by its rapid GI transit time, leading to a reduced time for absorption in chickens. 
After IV administration of DON3G to chickens and pigs, no hydrolysis to DON could be observed, indicating the 
absence of systemic hydrolysis for both species. For pigs, this confirms the findings of Nagl et al. (2014). After 
PO administration of DON3G to chickens, hydrolysis was not observed either. In contrast, after PO DON3G 
administration to pigs, only DON was recovered, indicating a complete presystemic hydrolysis of the absorbed 
fraction. Presystemic hydrolysis can take place at the level of GI microbiota, GI tissues, portal blood or the liver. 
To further determine the site of presystemic hydrolysis, blood was collected from the porcine vena porta, 
which drains the venous intestinal blood to the liver first. Interestingly, only DON was recovered and no DON3G 
was detected in these portal plasma samples after PO DON3G administration. This absence of DON3G in portal 
plasma as well as the absence of DON after IV DON3G administration, indicates that hydrolysis occurs at the 
site of the GI tract (microbiota or GI tissues) and not in portal blood nor in the liver. This is in accordance with 
previously reported in vitro results which reported that hydrolysis could be caused by intestinal microbiota and 
which have demonstrated the important role of microbiota composition and the abundance in the intestinal 
tract (Abbott 2004; Berthiller et al. 2011; Dall'Erta et al. 2013; Gratz et al. 2013; Hattori and Taylor 2009). 
Furthermore, β-glucosidase from humans and almonds proved incapable of DON3G hydrolysis to DON, a typical 
trait of micro-organisms (Berthiller et al. 2011). The observed lag time for DON absorption after PO 
administration of DON3G to pigs, 83.6 min, further supports the hypothesised intestinal hydrolysis of DON3G. 
This is also reflected in the significant higher tmax value of DON after PO DON3G administration in pigs. DON is 
mainly absorbed in the proximal part of the small intestine by means of passive diffusion. A less effective 
passive non-ionic diffusion is expected for DON3G as it is more polar and has a less favourable log D value (-
2.74) compared to DON (-0.97) at both physiological and acidic pH values (Maresca 2013). The pH in the 
stomach and duodenum of adult pigs is 4.4 and 6.4-7.4, respectively (Merchant et al. 2011). These rather low 
pH values are unfavourable for most GI commensal bacteria. When moving to more distal parts of the small 
intestine, the pH increases and a more abundant growth of microbiota is observed (Maresca 2013). 
Consequently, the probability of DON3G hydrolysis to DON is increased, resulting in the observed lag time of 
83.6 min. As chickens have a high bacterial load at the crop, thus before the small intestine, which is the main 
site of absorption, hydrolysis of DON3G to DON by GI microbiota would be expected after PO administration to 
chickens. For pigs, where the high bacterial load is located after the site of absorption, only limited hydrolysis 
to DON is expected. Remarkably, our observations were the opposite of these theoretical expectations. This 
discrepancy likely finds its cause in the bacterial species composition and abundance in both the chicken crop 
and pig distal small and large intestine. 
The microbiota of pigs and chickens consist mainly of the phyla Firmicutes and Bacteroidetes, accounting for 
approximately 90% and 80% of the relative abundance, respectively (Kim and Isaacson 2015; Waite and Taylor 
2015). The crop, anterior small intestine, duodenal and jejunal epithelial cells, and digesta of chicken are 
dominated by Lactobacillus spp. (Watkins and Kratzer 1983). The hydrolytic capacity of Lactobacillus spp. 
towards DON3G has been described (Berthiller et al. 2011). Of the tested L. amylovorus, crispatus, fermentum, 
gasseri, paracasei, rhamnosus and plantarum, only the latter was able to hydrolyse DON3G to DON, more 
specifically 34% after 4h incubation. This L. plantarum has been found in the GI tract of chickens, however it 
does not belong to the most abundant GI Lactobacillus species (Hilmi et al. 2007), in contrast, it is commonly 
found in human and other mammalian gastrointestinal tracts (de Vries et al. 2006). The hydrolytic capacities 
towards DON3G of Enterococcus, a large genus within Firmicutes species, has also been investigated. Of the 
seven tested species, E. avium was the only species unable to hydrolyse DON3G to DON. E. casseliflavus, 
durans, faecalis, faecium, gallinarum and mundtii all hydrolysed DON3G varying between 2% and 39% after a 4 
h incubation (Berthiller et al. 2011). The occurrence of both Enterococcus species has been described in the GI 
tract of both chickens and pigs. Possibly, the relative amounts of Enterococcus and Lactobacillus species in the 
GI microbiota could partially explain our in vivo findings. However, the GI microbiota of animals consists of a 
multitude of phyla and genus, demonstrating interspecies as well as intraspecies differences, and differing 
between intestinal sections, providing a multitude of options for the observed differences in hydrolysis 
between chickens and pigs. 
The mean (±SD) kaDON values in chickens and pigs were comparable, 0.0315±0.0173/min and 
0.0274±0.0107/min, respectively. For pigs kaDON values of 0.00995±0.00292/min (Eriksen et al. 2003), 
0.0310±0.0238/min (Goyarts and Dänicke 2006) and 0.0164±0.0161/min (Broekaert et al. 2015b) have been 
reported, and for chickens a kaDON of 0.0203±0.0101/min (Broekaert et al. 2015b) was previously described. The 
kaDON3G in chickens was slightly lower than that of DON, 0.0238±0.0203/min. For pigs no kaDON3G could be 
calculated as it was fully hydrolysed to DON after PO administration. The resulting kaDON after PO DON3G 
administration was 0.00501/min, significantly lower than the kaDON after DON administration. The kaDON after 
PO DON3G administration is influenced by presystemic hydrolysis, consequently this value is also determined 
by biotransformation in addition to absorption. 
With regards to clearance, mean (±SD) ClDON3G values of 11.4±1.2 and 3.17±0.81 mL/min/kg were obtained for 
chickens and pigs, respectively. ClDON values in chickens and pigs were 88.8±12.4 and 5.25±1.25 mL/min/kg, 
respectively. For chickens, a comparable ClDON of 120 mL/min/kg (Osselaere et al. 2013) and 102±12 mL/min/kg 
(Broekaert et al. 2015b) have previously been described. ClDON values in pigs of 9.30±3.95 mL/min/kg (acute PO) 
(Goyarts and Dänicke 2006), 5.30±1.64 mL/min/kg (chronic PO) (Goyarts and Dänicke 2006), 15.1±3.8 
mL/min/kg (acute PO) (Broekaert et al. 2015b) and a ClDON/F of 5.0±0.7 mL/min/kg (acute PO) (Devreese et al. 
2014) have been reported, which are in the same range as the results in this study. The obtained mean (±SD) 
VcDON and VpDON values for chickens were 1350±578 and 1087±211 mL/kg, respectively. For pigs, VcDON and 
VpDON values were comparable, i.e. 614±127 and 789±486 mL/kg respectively. For chickens VcDON3G and VpDON3G 
values of 290±188 and 284±167 mL/kg were obtained. A VdDON3G in pigs of 249±67 mL/kg was obtained using a 
one-compartmental model. The observed lower Vd values for DON3G indicate that DON3G is more confined to 
intravascular fluids than DON, which can be theoretically explained by its increased polarity compared to DON, 
resulting in less effective passive non-ionic diffusion into tissues. 
The mean (±SD) elimination half-lives (t1/2el) for DON in broilers and pigs were 18.8±2.1 min and 163±59 min 
(2.71 h), respectively. For pigs, t1/2el of 5.3±2.4 h (acute PO, two-compartmental model) (Goyarts and Dänicke 
2006), 2.4±0.7 h (acute PO, one-compartmental model) (Eriksen et al. 2003), 2.7±0.5 h (acute PO, one-
compartmental model) (Devreese et al. 2014) and 2.9 h (acute PO, two-compartmental model) (Broekaert et al. 
2015b) were observed. For broiler chickens comparable elimination half-lives of 27.9±6.9 min (IV) and 
38.2±11.2 min (acute PO) (Osselaere et al. 2013) and 17.9 min (acute PO) (Broekaert et al. 2015b) were also 
reported. The t1/2elDON3G values for chickens and pigs were 34.0±6.2 min and 54.1±3.0 min, respectively. 
Remarkably, the t1/2elDON3G compared to that of DON was increased for chickens and decreased for pigs, 
highlighting the difference between both species with respect to DON3G’s elimination. For pigs, this is mainly 
attributed to a lower Vd. For broiler chickens, additional to a lower Vd a reduced Cl was observed. 
HRMS 
The plasma concentration-time profiles of phase II metabolites are depicted in Figure 4 and Figure 5 for pigs 
and chickens, respectively. Since only semi-quantitative analysis was performed, absolute peak areas obtained 
on the HRMS instrument are depicted. For pigs, a first observation is that glucuronidation patterns after PO 
administration do not differ between systemic (vena jugularis) and presystemic (vena porta) plasma. This 
indicates that glucuronidation does not occur presystemically to a significant rate and extent. This hypothesis is 
further supported by practically identical observed mean glucuronidation ratios (area of DON-GlcA/ area of 
DON) after IV and PO administration, 4.94 and 4.98, respectively. For pigs, no sulfate conjugates were 
detected, in agreement with the previously reported lack of sulfation reactions in this species (Riviere and 
Papich 2013). In contrast chickens predominantly formed DON-3sulfate. The mean DON-3-sulfate/DON ratios in 
chickens after IV and PO DON administration were 392 and 9,890, respectively. The observed ratios are 
comparable to previously found values for IV and PO administration of DON to chickens of 243-453 and 1,365-
29,624, respectively (Devreese et al. 2015). This remarkable contrast in ratio between IV and PO 
administration, points towards a presystemic sulfation of DON, either by GI microbiota, GI tissues or a 
presystemic liver effect. In chickens, no glucuronidation was observed. The extensive and rapid sulfation in 
chickens might partially explain the relative resistance of this species towards the detrimental effects of DON.  
In conclusion, broiler chickens do not hydrolyse DON3G to DON in vivo. Additionally, DON3G has a low absolute 
oral bioavailability (3.79±2.68%) comparable to that of DON (5.56±2.05%). After PO DON3G administration to 
pigs only DON was recovered, indicating a complete presystemic hydrolysis of DON3G. However, the absorbed 
fraction is approximately 5 times lower than after PO DON administration, 16.1±5.4% compared to 81.3±17.4%. 
Analysis of phase II metabolites revealed that DON biotransformation in pigs consists mainly of 
glucuronidation, and in chickens predominantly sulfation occurs, which is absent in pigs. Phase II 
biotransformation is much more extensive for chickens than for pigs, which is a possible explanation for the 
differences in sensitivity of the latter species to DON. Furthermore, given the in vivo hydrolysis of DON3G in 
pigs, pigs are likely to be more sensitive to this modified mycotoxin compared to chickens. Although in vitro 
studies reported that DON3G is less toxic than DON, the demonstrated in vivo hydrolysis to DON in pigs, as well 
as the inter-species differences observed, indicate a decreased yet not neglectable toxicological relevance of 
DON3G and consequently warrant further research to establish a tolerable daily intake. 
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Figure 1. Graphical representation of the applied model for broiler chicken: DON IV (black, light red and dark 
red section), DON PO (blue, grey, light red and dark red section), DON3G IV (purple, light green and dark green 
section) and DON3G PO (blue, orange, light green and dark green section), IV=intravenous administration; 
kaDON=absorption rate constant of DON (1/min); kaDON3G=absorption rate constant of DON3G (1/min); 
ClDON=clearance of DON (mL/min/kg); QDON=intercompartment flow for DON (mL/min/kg); VcDON=central volume 
of distribution for DON (mL/kg); VpDON=peripheral volume of distribution for DON (mL/kg); ClDON3G=clearance of 
DON3G (mL/min/kg); QDON3G=intercompartment flow for DON3G (mL/min/kg); VcDON3G=central volume of 
distribution for DON3G (mL/kg); VpDON3G=peripheral volume of distribution for DON3G (mL/kg); FRAC=fraction 



























































Figure 2. Graphical representation of the applied model for pig: DON IV (black, light red and dark red section), 
DON PO (blue, grey, light red and dark red section), DON3G IV (purple and light green section) and DON3G PO 
(blue, grey and light red section + lag time). IV=intravenous administration; kaDON=absorption rate constant of 
DON (1/min); kaDON3G=absorption rate constant of DON3G (1/min); ClDON=clearance of DON (mL/min/kg); 
QDON=intercompartment flow for DON (mL/min/kg); VcDON=central volume of distribution for DON (mL/kg); 
VpDON=peripheral volume of distribution for DON (mL/kg); ClDON3G=clearance of DON3G (mL/min/kg); 







Figure 3. Systemic plasma (chickens and pigs) and vena porta plasma (pigs) concentration-time profiles of 
deoxynivalenol (DON) and deoxynivalenol-3-β-D-glucoside (DON3G) after oral (PO) and intravenous (IV) 
administration (post administration=p.a.) of DON (dose=500 µg DON/kg body weight) and DON3G (dose=774 
µg DON3G/kg body weight) to broiler chickens and of DON (dose=36 µg DON/kg body weight) and DON3G 
(dose=55.7 µg DON3G/kg body weight) to pigs (n=6 for systemic plasma, n=4 for plasma from vena porta). 
Values are presented as mean + or - SD. No DON was detected in chickens after DON3G administration. In pigs, 
no DON was detected after IV DON3G administration and no DON3G after PO DON3G administration. The 







Figure 4. Porcine plasma (systemic and vena porta) concentration-time profiles of deoxynivalenol (DON), 
deoxynivalenol-3-β-D-glucoside (DON3G) and deoxynivalenol-glucuronide (DON-GlcA) after oral (PO) and 
intravenous (IV) administration of DON (dose=36 µg DON/kg body weight) and DON3G (dose=55.7 µg 
DON3G/kg body weight) to pigs (n=3 for systemic plasma, n=3 for plasma from vena porta). Values are 
presented as mean + or - SD. 
 
 
Figure 5. Plasma concentration-time profiles of deoxynivalenol (DON) and deoxynivalenol-3-sulfate (DON3S) 
after oral (PO) and intravenous (IV) administration of DON (dose=500 µg DON/kg body weight) to broiler 
chickens (n=3). Values are presented as mean + SD. 
 
Table 1. Compound specific MRM ion transitions and MS-parameters for the analysis of DON, DON3G, DOM-1 
and 13C15-DON in broiler and pig plasma; Rt= retention time; IS= internal standard; a quantifier ion.  

















+ 203.4 14 0.25 




- 247.0 15 0.25 




+ 137.0 16 0.81 





263.0 10 0.25 
 
Table 2. Validation results for linearity (r & gof, 8 concentration points in the range LOQ-500 ng/mL), sensitivity 

















DON 0.9998 4.92% 0.47 1.0 85.3 65.9 77.2 
DOM-1 0.9997 7.05% 0.11 1.0 112.0 76.2 68.2 
DON3G 0.9997 7.58% 0.38 1.0 58.1 43.9 75.6 
Pig 
DON 0.9997 5.94% 0.01 0.5 67.5 65.4 97.0 
DOM-1 0.9999 3.98% 0.28 1.0 44.0 41.8 95.0 
DON3G 0.9998 4.98% 0.03 0.1 73.1 64.8 88.7 
 
Table 3. Validation results for within-day (n=6) and between-day precision (n=3x3) with corresponding accuracy 
at low (LOQ) and high (500 ng/mL) concentration level. 
  Within-day Between-day 
  Accuracy (%) Precision (RSD, %) Accuracy (%) Precision (RSD, %) 













DON 8.0 0.6 12.3 3.3 -9.5 -0.7 27.6 4.7 
DOM-1 15.6 0.7 24.1 4.6 -12.2 0.3 12.7 4.2 
DON3G 6.1 0.3 29.4 7.5 16.3 0.3 18.4 5.0 
Pig 
DON -1.3 0.8 31.4 3.3 -5.7 -0.8 28.8 3.6 
DOM-1 -7.7 -0.6 6.4 2.0 -2.3 1.0 18.2 3.4 
DON3G -11.4 -0.8 24.6 1.7 -1.1 -2.0 31.3 4.3 
 
 
Table 4. Toxicokinetic parameters, presystemic hydrolysis of the bioavailable fraction (%) and absolute oral 
bioavailability (F%) of DON and DON3G after IV and PO administration to broiler chickens and pigs (n=6).  
 
 Broiler chicken Pig 
 DON (IV&PO) DON3G (IV&PO) DON (IV&PO) DON3G IV DON3G PO 
kaDON (1/min) 0.0315±0.0173 - 0.0274±0.0107 - 0.00501±0.00160 
KeDON/βDON (1/min) 0.0369±0.0041 - 0.00425±0.00155 - 0.0217±0.0014 
t1/2elDON (min) 18.8±2.1 - 163±59 - 31.9±2.1 
ClDON (mL/min/kg) 88.8±12.4 - 5.25±1.25 - 25.9±2.8 
QDON (mL/min/kg) 86.7±40.7 - 17.4±11.3 - - 
VcDON (mL/kg) 1350±578 - 614±127 - 1196±717 
VpDON (mL/kg) 1087±211 - 789±486 - - 
tlag (min) - - - - 83.6±5.6 
kaDON3G (1/min) - 0.0238±0.0203 - - - 
keDON3G/βDON3G (1/min) - 0.0204±0.0037 - 0.0128± 
0.0007 
- 
t1/2elDON3G (min) - 34.0±6.2 - 54.1±3.0 - 
ClDON3G (mL/min/kg) - 11.4±1.2 - 3.17±0.81 - 
QDON3G (mL/min/kg) - 27.7±25.8 - - - 
VcDON3G (mL/kg) - 290±188 - 249±67 - 
VpDON3G (mL/kg) - 284±167 - - - 
FRAC (%) 5.56±2.05 3.79±2.60 81.3±17.4 - 16.1±5.4** 
Pres.Hydr. (%) - 0 - - 100 
F (%) 5.56±2.05 3.79±2.68 81.3±17.4 - 0* 
Cmax (ng/mL) 7.40±7.35 16.6±10.4 23.7±9.8 - 3.88±2.0** 
tmax (min) 30.0±22.5 43.1±49.4 44.4±39.1 - 225±100** 
 
Values are presented as mean ± SD. For pigs, the DON3G PO parameters have been calculated simultaneously 
on all pooled pig PO DON3G data, as a result no SD could be calculated, instead coefficients of variation of the 
models’ predicted versus the observed concentrations are given. kaDON=absorption rate constant for DON 
(1/min); keDON=elimination rate constant for DON (1/min); βDON=disposition rate constant for DON (1/min); 
t1/2elDON=elimination half-life of DON (min); ClDON=clearance of DON (mL/min/kg); QDON=intercompartmental 
flow for DON (mL/min/kg); VcDON=central volume of distribution for DON (mL/kg); VpDON=peripheral volume of 
distribution for DON (mL/kg); tlag=absorption lag time (min); kaDON3G=absorption rate constant of DON3G 
(1/min); keDON3G=elimination rate constant for DON3G (1/min); βDON3G=disposition rate constant for DON3G 
(1/min); t1/2elDON3G=elimination half-life of DON3G (min); ClDON3G=clearance of DON3G (mL/min/kg); 
QDON3G=intercompartmental flow for DON3G (mL/min/kg); VcDON3G=central volume of distribution for DON3G 
(mL/kg); VpDON3G=peripheral volume of distribution for DON3G (mL/kg); FRAC=absorbed fraction; 
Pres.Hydr.=percentage of the total dose that is hydrolysed presystemically to DON and absorbed as DON (%); 
F=absolute oral bioavailability (%); Cmax=maximum plasma concentration for DON (ng/mL); tmax= time to 
maximum plasma concentration for DON (min); * and ** statistically significant difference at p<0.05 and 
p<0.01, respectively, compared to DON values in the same animal species.  
 
 
 
